.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,936,590

« Back to Dashboard
Patent 6,936,590 protects XIGDUO XR and FARXIGA and is included in two NDAs.

Summary for Patent: 6,936,590

Title: C-aryl glucoside SGLT2 inhibitors and method
Abstract:A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula ##STR1## alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).
Inventor(s): Washburn; William N. (Titusville, NJ), Ellsworth; Bruce (Princeton, NJ), Meng; Wei (Pennington, NJ), Wu; Gang (Princeton, NJ), Sher; Philip M. (Plainsboro, NJ)
Assignee: Bristol Myers Squibb Company (Princeton, NJ)
Application Number:10/264,410
Patent Claim Types:
see list of patent claims
Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 18th percentile
Forward Citations: 10th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Ab
XIGDUO XR
dapagliflozin propanediol; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205649-002Oct 29, 2014RXNo6,936,590► subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca Ab
XIGDUO XR
dapagliflozin propanediol; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205649-001Oct 29, 2014RXNo6,936,590► subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca Ab
XIGDUO XR
dapagliflozin propanediol; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205649-004Oct 29, 2014RXYes6,936,590► subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc